Table 2 |
||||
|
Minimum inhibition concentration of PRE and CuSO4 alone and in combination against ten isolates each of MRSA, MSSA and Panton-Valentine Leukocidin positive CA-MSSA. |
||||
|
Isolates type |
No. of isolates |
MIC (mg/mL) |
||
|
PRE |
CuSO4 |
*PRE/CuSO4 |
||
|
|
||||
|
MRSA |
1 |
12.5 |
3.125 |
6.25/1.563 |
|
1 |
25 |
1.563 |
6.25/0.781 |
|
|
2 |
25 |
3.125 |
12.5/1.563 |
|
|
3 |
25 |
1.563 |
12.5/0.781 |
|
|
2 |
12.5 |
1.563 |
6.25/0.781 |
|
|
1 |
12.5 |
1.563 |
6.25/0.781 |
|
|
MSSA |
1 |
25 |
1.563 |
6.25/0.391 |
|
3 |
25 |
1.563 |
12.5/0.781 |
|
|
1 |
25 |
3.125 |
6.25/0.781 |
|
|
1 |
12.5 |
1.563 |
3.125/0.391 |
|
|
1 |
12.5 |
0.782 |
3.125/0.196 |
|
|
3 |
12.5 |
1.563 |
6.25/0.781 |
|
|
PVL |
3 |
25 |
1.563 |
6.25/0.391 |
|
4 |
25 |
3.125 |
6.25/0.781 |
|
|
2 |
25 |
0.781 |
6.25/0.195 |
|
|
1 |
25 |
1.563 |
12.5/0.781 |
|
|
|
||||
|
*For the PRE/CuSO4 combinations the fixed ratio for each component is maintained as shown. |
||||
|
Gould et al. BMC Complementary and Alternative Medicine 2009 9:23 doi:10.1186/1472-6882-9-23 |
||||
